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β2-Chimaerin, an intracellular receptor for the second messenger diacylglycerol and phorbol esters, is a GTPase-activating protein (GAP)
specific for Rac. β2-Chimaerin negatively controls many Rac-dependent pathophysiological events including tumor development. However, the
regulatory mechanism of β2-chimaerin remains largely unknown. Here we report that β2-chimaerin is tyrosine-phosphorylated by Src-family
kinases (SFKs) upon cell stimulation with epidermal growth factor (EGF). Mutational analysis identified Tyr-21 in the N-terminal regulatory
region as a major phosphorylation site. Intriguingly, the addition of SFK inhibitor and the replacement of Tyr-21 with Phe (Y21F) markedly
enhanced Rac-GAP activity of β2-chimaerin in EGF-treated cells. Moreover, the Y21F mutant inhibited integrin-dependent cell spreading, in
which Rac1 plays a critical role, more strongly than wild-type β2-chimaerin. These results suggest Tyr-21 phosphorylation as a novel, SFK-
dependent mechanism that negatively regulates β2-chimaerin Rac-GAP activity.
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Rac1 is a member of the Rho small GTPase family together
with RhoA and Cdc42 [1–3]. The active form of Rac1 interacts
with various effectors to initiate downstream signaling events
that control cell morphology, actin dynamics, migration,
metastasis, gene expression, apoptosis and cell cycle. Moreover,
Rac1 was reported to be required for Src-induced transforma-
tion [4]. Rac GTPase is known to act as a molecular switch,
cycling between an active GTP-bound state (Rac-GTP) and an
inactive GDP-bound state (Rac-GDP). This switch is regulated
by the three groups of effector molecules: guanine nucleotide
exchange factors (GEFs); guanine nucleotide dissociation
inhibitors; and GTPase-activating proteins (GAPs). The activa-
tion state of Rac is therefore dependent on the balance of
activities of these effector proteins. In turn, these regulatory
molecules themselves need to operate also under tight control.
Studies in vitro and in vivo have shown that a GAP domain
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GTPases [5,6]. Chimaerin comprises a family of four isoforms
(α1- or ‘n’-, α2-, β1- and β2-chimaerins), which are splice
variants of the α- and β-chimaerin genes. The common
structural feature among all chimaerins is, in addition to the
GAP domain, the presence of the C1 domain, a 50- to 51-amino
acid motif that was first found in protein kinase C (PKC) [7].
The main structural difference between the spliced variants is
due to the presence of a Src homology-2 (SH2) domain at the
N-termini of α2- and β2-chimaerins [5,6]. The SH2 domain is
presumed to be competent to bind phosphotyrosine-containing
proteins [8], but its physiological partner remains unknown.
Chimaerins are implicated in many physiological functions
through Rac inactivation [5,6]. With regard to β2-chimaerin,
down-regulation of its message level was found in some types
of cancers such as high-grade glioma [9] and mastocarcinoma
[10,11], suggesting that reduced expression of this gene
contributes to the development of the tumors. Indeed,
β2-chimaerin was found to inhibit proliferation, migration,
and metastasis of mammary carcinoma cells [10,11]. β2-
Chimaerin was recently reported to be activated by phorbol
myristate acetate (PMA) [12] and diacylglycerol (DAG)
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(EGFR)-phospholipase Cγ (PLCγ) pathway [13] in intact
cells. However, despite physiological importance, the regula-
tory mechanism of β2-chimaerin is still largely unknown.
In the present study, we found that β2-chimaerin was
phosphorylated at Tyr-21 in the N-terminal regulatory region
through the Src-family kinase (SFK) pathway in response to
EGF. Moreover, by using an SFK inhibitor, SU6656, and a non-
phosphorylatable mutant, we showed a novel, negative
regulatory mechanism for β2-chimaerin that was mediated by
the SFK-dependent phosphorylation at Tyr-21.
2. Materials and methods
2.1. Antibodies
To raise anti-β-chimaerin antibody, a synthetic peptide RRAALTHNDNHF-
NYEK(C) (amino acid 198–213 and 25–40 in β2- and β1-chimaerins,
respectively) [9,14] was coupled to keyhole limpet hemocyanin and used as
an antigen. Two female rabbits were immunized with 200 μg of the cross-linked
peptide mixed with adjuvant. Affinity-purified anti-β-chimaerin was obtained
using Sulfolink coupling gel (Pierce Biotechnology, Rockford, IL) linked to the
antigen peptide. This antibody did not react with α1- and α2-chimaerins (data
not shown). Anti-Rac1 monoclonal antibody 23A8 and anti-phosphotyrosine
monoclonal antibody 4G10 were from Upstate Biotechnology (Lake Placid,
NY). Anti-v-Src monoclonal antibody Ab-1 was from Merck Biosciences
(Tokyo, Japan). Anti-Fyn monoclonal antibody was from BD Biosciences
(Tokyo, Japan). Anti-green fluorescent protein (GFP) monoclonal antibody B-2,
normal rabbit IgG, and Protein A/G-Plus Agarose were from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-GFP polyclonal antibody (living colors
full-length A.v. polyclonal antibody) was from Takara Bio (Tokyo, Japan). Anti-
FLAG M2 monoclonal antibody was from Sigma-Aldrich (Tokyo, Japan).
2.2. Plasmid constructs
The β2-chimaerin cDNA was cloned by polymerase chain reaction (PCR)
using human brain QUICK-Clone cDNA (Takara Bio), KOD PLUS DNA
polymerase (Toyobo, Tokyo, Japan) and a pair of primer, b2c-forward (5′-ccgaa
ttcga tggca gcgtc cagca actcc-3′) and b2c-reverse (5′-ccgtc gacgg attag aataa
aacgt cttcg ttttc-3′). The resulting EcoRI–SalI cDNA fragment, which encodes
β2-chimaerin (a 468 amino acid form) [9], was subcloned into pECFP-C1
(Takara Bio) and p3XFLAG-CMV-7.1 (Sigma) at the EcoRI/SalI site of each
expression vector. Point-mutated β2-chimaerins Y21F and Y153F were
generated using Quickchange Site-directed Mutagenesis kit (Stratagene, La
Jolla, CA). The cDNA of human α2-chimaerin was amplified using a pair of
primer, a2c-forward (5′-ttcga attct atggc cctga ccctg tttg-3′) and a2c-reverse (5′-
taccg tcgac ttaaa ataaa atgtc ttcgt ttttg-3′) and then subcloned as described above.
The cDNA of human Fyn was also amplified using a pair of primer, fyn-forward
(5′-tggaa ttcag ataat gggct gtgtg-3′) and fyn-reverse (5′-accgt cgact tacag gtttt
cacca g-3′), and subcloned into pcDNA3.1 (Invitrogen, Tokyo, Japan) at the
EcoRI/SalI site. The amplification of the Lck cDNAwas achieved using human
spleen Quick-Clone (Takara Bio), a pair of primer, lck-forward (5′-aagaa ttcac
catgg gctgt ggctg cagct ca-3′) and lck-reverse (5′-aatct cgagt caagg ctgag gctgg
tactg gccc-3′). The amplified cDNA was subcloned into pcDNA3.1 at the
EcoRI/XhoI site. The authenticity of the cDNA constructs was confirmed by
DNA sequencing. pUSEamp-c-Src was perchased from Upstate Biotechnology.
2.3. Cell culture and transfections
COS-7 cells were maintained in Dulbecco's modified Eagle's medium
(DMEM) containing 10% fetal bovine serum at 37 °C in an atmosphere
containing 5% CO2. COS-7 cells (∼1×106 cells/60-mm dish) were transiently
transfected with cDNAs using LipofectAMINE Plus transfection reagent
according to the instructions from the manufacturer (Invitrogen). After 24 h
of transfection, cells were serum-starved by incubation with DMEM containing
0.1% bovine serum albumin, and then used for further analysis.2.4. Immunoprecipitation and Western blotting
Immunoprecipitation and Western blotting were performed as described
previously [15,16].
2.5. In vitro Src kinase assay
Escherichia coli cells (XL1-blue, Stratagene) transformed by pGEX-6P
vector (GE Healthcare Bio-Sciences) harboring the cDNA encoding either β2-
chimaerin, β2-chimaerin-Y21F or β2-chimaerin-Y153F were grown to an
absorbance at 600 nm of 0.5. After addition of 0.1 mM isopropyl β-D-
thiogalactoside, the cells were cultured at 20 °C for 24 h and harvested by
centrifugation (2000×g for 15 min). The cell pellet was lysed by sonication in
50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA,
1% Triton X-100 and Complete™ protease inhibitor mixture, and the debris was
removed by centrifugation at 15,000×g for 10 min. The glutathione S-
transferase (GST)-tagged β2-chimaerin fusion protein was purified using
glutathione Sepharose 4B (GE Healthcare Bio-Sciences). To delete the GST tag,
the purified protein was digested with PreScission protease (GE Healthcare Bio-
Sciences) at 5 °C for 4 h. The cleaved GST portion and PreScission protease
were removed by absorption with glutathione Sepharose 4B.
Affinity-purified β2-chimaerin and its mutants (1 μg) were added to kinase
reaction mixture (40 μl) containing 60 mM HEPES, pH 7.5, 5 mM MgCl2,
5 mMMnCl2, 3 mMNa3VO4, 1.25 mM dithiothreitol, 10 mMATP, and 50 ng of
either active Src, Yes, Lck (Cell Signaling Technology, Beverly, MA) or Fyn
(Upstate Biotechnology). Reactions were carried out for 30 min at 25 °C and
then terminated by adding SDS sample buffer, followed by boiling. Tyrosine
phosphorylation of β2-chimaerin was analyzed by Western blot using anti-
phosphotyrosine monoclonal antibody 4G10 as described above.
2.6. Affinity precipitation of active Rac1
COS-7 cells expressing 3xFLAG-tagged proteins were serum-starved for 5 h
prior to the pre-treatment with 1 mMNa3VO4 in the presence or absence of other
inhibitors as indicated. After the pretreatment for 30 min, cells were stimulated
with 100 ng/ml EGF for 15 min, washed once with ice-cold phosphate-buffered
saline, and harvested with 500 μl of lysis buffer containing 25 mM Tris–HCl
(pH 7.5), 150 mM NaCl, 5 mM MgCl2, 1% NP-40, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 5% glycerol, Complete™ protease inhibitor
mixture (Roche Molecular Biochemicals) and 5 μg of GST-fused p21-binding
domain (PBD) of p21-activated kinase (PAK) (GST-PAK-PBD, Cytoskeleton,
Denver, CO), which specifically interacts with GTP-bound Rac1 and Cdc42.
Cell extracts were centrifuged at 12,000×g for 5 min at 4 °C to give cell lysates.
To precipitate Rac1-GTP associated with GST-PAK-PBD, 20 μl of glutathione-
Sepharose 4B beads were added to the lysates and then further incubated at 4 °C
for 30 min with constant rocking. The bead pellets were washed 3 times with
500 μl of wash buffer containing 25 mM Tris–HCl (pH 7.5), 150 mM NaCl,
5 mM MgCl2, 0.1% NP-40 and 1 mM dithiothreitol, and finally suspended in
50 μl of SDS sample buffer. Proteins extracted were analyzed by Western
blotting. The GTP-bound form of Rac1 thus recovered and total Rac1 in cell
lysates were detected by Western blotting using anti-Rac1 monoclonal antibody.
2.7. Cell spreading assay
Cell spreading assay was carried out as described previously [16].
3. Results
3.1. Cell stimulation with EGF induces tyrosine
phosphorylation of β2-chimaerin
To date no report has been available concerning phosphor-
ylation of chimaerins. In an attempt to explore the regulatory
mechanisms of β2-chimaerin, we first determined whether the
protein is tyrosine-phosphorylated. Because Wang et al.
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EGF-induced Rac signaling [13], we chose EGF as a cell
stimulant. When COS-7 cells expressing β2-chimaerin were
stimulated with EGF (100 ng/ml) for 15 min in the presence of a
tyrosine phosphatase inhibitor Na3VO4, we found that β2-
chimaerin was clearly tyrosine-phosphorylated by endogenous
tyrosine kinase(s) (Fig. 1A). This reaction was rapid (detectable
at 5 min) and increased by 30 min of stimulation (Fig. 1B).
Because the tyrosine-phosphorylated band was not detectable in
the absence of Na3VO4, the tyrosine phosphorylation of β2-
chimaerin could be a short-lived event under a strict control of a
tyrosine phosphatase. In contrast, EGF did not significantly
augment tyrosine phosphorylation of α2-chimaerin (Fig. 1C),
indicating that the EGF-induced tyrosine phosphorylation is
specific for the β2 isoform.
Although we thoroughly examined more than ten cell lines,
our antibody, which could clearly detect β2-chimaerin protein
overexpressed, failed unfortunately to detect the cellular β2-Fig. 1. EGF-induced tyrosine phosphorylation of β2-chimaerin. (A) COS-7 cells
were transfected with either pECFP-β2-chimaerin or pECFP alone. Cells were
serum-starved for 5 h, preincubated with 1 mM Na3VO4 for 30 min, and
subsequently stimulated with 100 ng/ml EGF for 15 min prior to cell lysis. CFP-
β2-chimaerin and CFP were immunoprecipitated using anti-GFP antibody and
analyzed by Western blotting (WB) using anti-phosphotyrosine (PY) and anti-
GFP antibodies. The blots are quantified and relative intensities of the bands of
tyrosine-phosphorylated β2-chimaerins, which are normalized for total levels,
are shown at the bottom. (B) COS-7 cells expressing CFP-β2-chimaerin were
serum-starved, pretreated with 1 mM Na3VO4 for 30 min, and then stimulated
with 100 ng/ml EGF for the periods indicated. Immunoprecipitated CFP-β2-
chimaerin was analyzed by Western blotting as described above. (C) COS-7
cells were transfected with either pECFP-β2-chimaerin or pECFP-α2-
chimaerin. The cells were starved and stimulated with EGF, and tyrosine
phosphorylation of the chimaerins was analyzed by Western blotting as
described in (A). In (A–C), representative results of at least two independent
experiments are shown.chimaerin protein. Thus, we could not analyze the EGF-
dependent tyrosine phosphorylation of endogenous β2-chi-
maerin. To detect the endogenous tyrosine phosphorylation of
β2-chimaerin, it was necessary to find both an organ highly
expressing the GAP and a cell stimulation inducing tyrosine
phosphorylation of the GAP at a high stoichiometry. In this
context, we confirmed that β2-chimaerin is enriched in the adult
rat cerebellum as already reported in [17]. H2O2 is known to be
generated by cell stimulation with EGF [18] and to induce
activation of SFKs in some cells [19]. Indeed, we found that
H2O2 slightly augmented tyrosine phosphorylation of β2-
chimaerin (data not shown). In addition to H2O2, EGF
stimulation is known to produce DAG [20]. PMA, a potent
analog of DAG, has been reported to bind to the C1 domain of
β2-chimaerin [21] and to induce subcellular redistribution of
the GAP in a C1 domain-dependent manner [22]. However,
PMA-induced tyrosine phosphorylation of β2-chimaerin was
not detectable (data not shown). Intriguingly, we unexpectedly
found that a simultaneous treatment with PMA and H2O2
synergistically and more markedly enhanced (∼16-fold) the
tyrosine phosphorylation of β2-chimaerin overexpressed in
COS-7 cells when compared with EGF stimulation (Suppl. Fig.
1A). Based on these findings, we examined the tyrosine
phosphorylation of endogenous β2-chimaerin using rat cere-
bellar cell suspension stimulated with PMA plus H2O2. As
shown in Suppl. Fig. 1B, the tyrosine phosphorylation of
endogenous β2-chimaerin was weakly but clearly detected.
3.2. The SFK signaling pathway is responsible for tyrosine
phosphorylation of β2-chimaerin
EGF is known to activate SFKs including c-Src and Fyn
[23–25]. In order to investigate whether the tyrosine phosphor-
ylation of β2-chimaerin is mediated by SFK, COS-7 cells
expressing β2-chimaerin were treated with an SFK specific
inhibitor SU6656 [26–29] prior to EGF stimulation. SU6656
considerably reduced the EGF-induced tyrosine-phosphoryla-
tion of β2-chimaerin (Fig. 2A), indicating that the SFK pathway
at least in part participates in the tyrosine phosphorylation of
β2-chimaerin induced by EGF. Moreover, another SFK
inhibitor PP2 also inhibited the EGF-induced tyrosine phos-
phorylation, whereas its inactive analog PP3 did not (Fig. 2A).
Conversely, overexpression of c-Src and Fyn, which are
ubiquitously expressed [30] and were confirmed to be endoge-
nously expressed in COS-7 cells (see Fig. 3B), substantially
augmented the tyrosine phosphorylation (Fig. 2B and C),
further supporting the involvement of SFKs. Although Lck, a
lymphocyte-specific SFK [30], is not detectable in COS-7 cells,
this tyrosine kinase also augmented the tyrosine phosphoryla-
tion (Fig. 2C). These results suggest that a broad range of SFK
is capable of phosphorylating β2-chimaerin.
We next determined whether SFKs can directly phosphor-
ylate β2-chimaerin in vitro. Incubation of bacterially-
expressed/purified β2-chimaerin with purified active Src (Fig.
2D), Fyn, Yes or Lck (data not shown) revealed that β2-
chimaerin was directly tyrosine-phosphorylated by these
tyrosine kinases in vitro, allowing us to speculate that a broad
Fig. 2. β2-Chimaerin is phosphorylated through the SFK pathway. (A) COS-7 cells expressing CFP-β2-chimaerin were serum-starved for 5 h, pretreated with 1 mM
Na3VO4 plus either 10 μM SU6656, 10 μM PP2, 10 μM PP3 or 0.2% DMSO (Control) for 30 min, and subsequently stimulated with 100 ng/ml EGF for 15 min.
(B) COS-7 cells were co-transfected with pECFP-β2-chimaerin and pUSEamp-c-Src as indicated. The cells were starved and stimulated with EGF as described in (A).
(C) COS-7 cells were co-transfected with pECFP-β2-chimaerin and pUSEamp-c-Src, pcDNA3.1-Lck or pcDNA3.1-Fyn as indicated. The cells were starved and
stimulated with EGF as described in (A). (A–C) CFP-β2-chimaerin was immunoprecipitated using anti-GFP antibody and analyzed by Western blotting (WB) using
anti-phosphotyrosine (PY) and anti-GFP antibodies. In (B), anti-Src antibody was also used. The blots are quantified and relative intensities of the bands of tyrosine-
phosphorylated β2-chimaerin, which are normalized for total β2-chimaerin levels, are shown at the bottom of blots. Error bars represent S.D. for three independent
experiments. Statistical significance was determined using Student's t-test (*Pb0.05; **Pb0.01). (D) Purified β2-chimaerin was incubated with or without purified
active Src as described under Materials and methods. After the phosphorylation reaction, β2-chimaerin was resolved by SDS-PAGE. The levels of tyrosine-
phosphorylated β2-chimaerin were analyzed by Western blotting using anti-phosphotyrosine (PY) and anti-β-chimaerin antibodies. Representative results of three
independent experiments are shown.
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as well.
3.3. Mapping of tyrosine phosphorylation sites in β2-chimaerin
We used a mutational approach to determine which tyrosine
residues are phosphorylated. Tyr-21 and Tyr-153 in β2-
chimaerin are predicted to be phosphorylated by SFK
(Scansite.com). When cells were stimulated with EGF, β2-
chimaerin-Y21F showed a substantially less tyrosine phosphor-
ylation level than the wild-type (WT) protein, while the
phosphorylation of β2-chimaerin-Y153F was not much
decreased (Fig. 3A). In cells overexpressing c-Src or Fyn, thetyrosine phosphorylation of β2-chimaerin-Y21F was markedly
decreased again (Fig. 3B). We verified that the Tyr-21 was also
phosphorylated through the SFK signaling pathway in COS7
cells stimulated with PMA plus H2O2 (data not shown),
suggesting that, despite the different extent of tyrosine
phosphorylation, EGF and PMA/H2O2 utilize partly the
common pathway that phosphorylates the same tyrosine residue
of β2-chimaerin. In phosphorylation in vitro by c-Src, β2-
chimaerin-Y21F exhibited a markedly reduced tyrosine phos-
phorylation level compared with β2-chimaerin-WT, whereas
β2-chimaerin-Y153F was phosphorylated by c-Src to a similar
extent to the wild type protein (Fig. 3C). Essentially the same
results were obtained with Fyn (data not shown). These results
Fig. 3. β2-Chimaerin is phosphorylated at Tyr21. (A) COS-7 cells expressing CFP-β2-chimaerin (WT) or its mutants (Y21F and Y153F) were starved for 5 h,
pretreated with 1 mM Na3VO4 for 30 min, and subsequently stimulated with 100 ng/ml EGF for 15 min. CFP-β2-chimaerin was immunoprecipitated using anti-GFP
antibody and analyzed by Western blotting (WB) using anti-phosphotyrosine (PY) and anti-GFP antibodies. (B) COS-7 cells were co-transfected with plasmid
encoding CFP-β2-chimaerin (WT or Y21F) and SFKs (Src or Fyn) as indicated. The cells were starved and stimulated with EGF, and tyrosine phosphorylation of the
chimaerins was analyzed and quantified as described in (A). (C) Purified β2-chimaerin (WT), β2-chimaerin-Y21F (Y21F) or β2-chimaerin-Y153F (Y153F) was
applied to in vitro Src kinase assay as described in Fig. 2D. (A–C) The blots are quantified and relative intensities of the bands of tyrosine-phosphorylated β2-
chimaerin, which are normalized for total β2-chimaerin levels, are shown at the bottom of blots. Error bars represent S.D. for three independent experiments. Statistical
significance was determined using Student's t-test (*Pb0.05; **Pb0.01).
1411M. Kai et al. / Biochimica et Biophysica Acta 1773 (2007) 1407–1415collectively indicate that Tyr-21 in β2-chimaerin is a major
tyrosine phosphorylation site by SFKs. However, these results
also demonstrate that, in addition to Tyr-21, the GAP contains
other tyrosine phosphorylation sites.
3.4. SFK-dependent phosphorylation at Tyr-21 is involved in
negative regulation of β2-chimaerin activity
To explore functional implication of the tyrosine phosphor-
ylation of β2-chimaerin, we examined the effects of the SFK
inhibitor SU6656 on β2-chimaerin Rac-GAP activity in EGF-
stimulated cells. We confirmed that EGF stimulation increased
the Rac1-GTP levels (∼2.5-fold) (Fig. 4A). Although the
expression of β2-chimaerin slightly reduced Rac-GTP levels by
60–70%, EGF still markedly augmented the active Rac1 levels.
However, in the presence of SU6656, EGF failed to
significantly increase the Rac1-GTP levels, indicating that the
inhibition of SFK activity apparently enhanced β2-chimaerin
Rac-GAP activity. These results therefore suggest the possibi-lity that phosphorylation by SFKs is involved in the negative
regulation of the β2-chimaerin GAP activity.
To investigate whether the effect of the SFK inhibitor on
β2-chimaerin activity (Fig. 4A) results from the suppression
of phosphorylation at Tyr-21 of β2-chimaerin, we next
determined Rac-GAP activity of the non-phosphorylatable
mutant (Y21F). As observed for the treatment with SU6656
(Fig. 4A), Rac1-GTP levels were not significantly increased
by EGF stimulation in cells expressing the Y21F mutant (Fig.
4B), indicating that the Y21F mutant is apparently more active
than the WT protein in EGF-stimulated cells. On the other
hand, the Y153F mutant did not significantly affect the Rac1-
GTP levels, thus serving as the negative control. In this
experiment, we confirmed that the expression levels of Rac-
GEFs, Tiam1 and Vav2, which were reported to be activated
by Src [4], were not altered by the expression of the Y21F
mutant (data not shown). These data strongly suggest the
importance of phosphorylation of Tyr-21 in the negative
control of β2-chimaerin GAP activity.
Fig. 4. Tyrosine phosphorylation of β2-chimaerin modulates its GAP activity.
COS-7 cells were transfected with either empty p3xFLAG-CMV vector
(Vector), p3xFLAG-CMV-β2-chimaerin (WT), p3xFLAG-CMV-β2-chimaerin-
Y21F (Y21F) or p3xFLAG-β2-chimaerin-Y153F (Y153F) as indicated. The
cells were serum-starved for 5 h and stimulated with 100 ng/ml EGF for 15 min.
In (A), the starved cells were preincubated with or without 25 μM SU6656 for
30 min prior to EGF stimulation. GTP-bound Rac1 was pulled down from cell
lysates by using GST-PAK-PBD as described under Materials and methods.
GTP-bound Rac1 (Pull down) and total Rac1 in cell lysates (Input) were
detected by Western blotting (WB) with anti-Rac1 antibody. The amount of β2-
chimaerin in cell lysates (Input) was also evaluated by Western blotting. The
blots are quantified and relative GTP-Rac1 levels normalized for total Rac levels
are shown at the bottom. Error bars represent S.E. for five (A) and three (B)
independent experiments. Statistical significance was determined using
Student's t-test (*Pb0.05; **Pb0.01).
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an open (active) form. The open form protein showed high
affinity for PMA (localization to the membrane fraction in the
presence of low concentrations of PMA) [21]. However, affinity
for PMA of the Y21F mutant was not appreciably affected(Suppl. Fig. 2), indicating that this mutant does not sponta-
neously convert to an open form. Thus, it seems likely that the
inhibition of phosphorylation at Tyr-21, but not the Y21F
mutation itself, is essential to enhance GAP activity.
As an independent experiment to determine if the Y21F
mutation affects GAP β2-chimaerin activity, we analyzed
another biological event, integrin-dependent cell spreading, in
which the role of Rac1 is well defined [31,32]. We expressed
CFP (cyan fluorescent protein)-tagged β2-chimaerin and its
Y21F mutant in COS-7 cells and observed morphological
changes of the cells expressing the CFP-tagged proteins. COS-
7 cells rapidly adhered to fibronectin-coated coverslips and
spread considerably by 15 min after replating (Fig. 5A and B).
This morphological change was suppressed by the expression
of β2-chimaerin. However, the Y21F mutant suppressed the
spreading more effectively than the WT protein. This result is
consistent with the notion that the phosphorylation of Tyr-21
negatively controls β2-chimaerin GAP activity. Throughout
these experiments for cell spreading assay, the transfection
efficiencies of β2-chimaerin and its mutant were almost
unchanged (∼40%) (data not shown), and Western blot
analysis showed that these proteins were expressed at almost
the same levels (Fig. 5C). Therefore, we consider that the
differences in cell morphology are not caused by variable
expression levels of the protein constructs.
4. Discussion
β2-Chimaerin has been repeatedly implicated in the negative
control of a variety of Rac-regulated events, but there has been
little understanding of the regulatory mechanisms of the GAP
activity. Moreover, to date no report has described phosphor-
ylation of chimaerins. In the present study, we report SFK-
dependent phosphorylation at Tyr-21 within the N-terminal
regulatory region of β2-chimaerin, and further demonstrate a
novel regulatory mechanism for the GAP that is mediated by the
phosphorylation at Tyr-21.
When cells were stimulated with EGF, Na3VO4 (a tyrosine
phosphatase inhibitor) was added because the phosphorylation
at Tyr-21 of β2-chimaerin was not detectable in the absence of
Na3VO4. In turn, this observation implies that the tyrosine
phosphorylation of β2-chimaerin could be a short-lived event
strictly controlled by a tyrosine phosphatase. Moreover, this
phosphorylation was dependent on the physiological cell
stimulation, EGF, (Fig. 1A) and occurred highly selectively
because α2-chimaerin, a closely related isoform, was not
tyrosine-phosphorylated under the same conditions (Fig. 1C).
Furthermore, the Y21F mutation of β2-chimaerin affected the
Rac1-GTP levels and fibronectin-dependent cell spreading
more significantly than the WT protein (Figs. 4 and 5). Thus,
we conclude that the phosphorylation at Tyr-21 is physiologi-
cally significant.
The flanking sequence of Tyr-21 (DAEEY21QPPI, where
underlines indicate residues identical or similar to the
corresponding residues in the canonical phosphorylation site
motif for SFK represented by c-Src) partly fulfils the canonical
phosphorylation site motif for c-Src [D(E/D)(E/D/G)(I/V/L)Y*
Fig. 5. Effect of β2-chimaerin Y21F mutant expression on cell spreading induced by fibronectin. (A) COS-7 cells were transfected with plasmid encoding CFP
(Vector), CFP-β2-chimaerin (WT) or CFP-β2-chimaerin-Y21F (Y21F) as indicated. Cells were serum-starved, trypsinized, and then replated on fibronectin (Fn)- or
poly-L-lysine (PL)-coated coverslips for 15 min. Cells were fixed, permeabilized, and stained for F-actin. Arrowheads indicate CFP-expressing cells with a spread
phenotype, and arrows denote CFP-expressing cells that did not spread. Scale bars, 20 μm. (B) Spreading was quantified by counting the CFP-expressing cells with a
spread phenotype. For each experiment, N50 cells were counted. Error bars represent S.E. for three independent experiments. Statistical significance was determined
using Student's t-test (*Pb0.05; **Pb0.01). (C) Western blot of CFP-tagged proteins expressed in COS-7 cells using anti-GFP antibody. A representative of twice
repeated experiments is shown.
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site [33]. Thus, it comes as no surprise that β2-chimaerin was
directly phosphorylated at Tyr-21 by SFKs including c-Src,
Fyn, Yes and Lck in vitro (Fig. 2D and data not shown). It istherefore possible to speculate that this direct phosphorylation
of Tyr-21 by SFK takes place also in intact cells. The results
obtained in Figs. 2C and 3B indicate that a broad range of SFK
can phosphorylate β2-chimaerin. We found that, in response to
1414 M. Kai et al. / Biochimica et Biophysica Acta 1773 (2007) 1407–1415cell stimulation with PMA plus H2O2, the Tyr-21 was also
phosphorylated in a SFK-dependent manner (data not shown),
suggesting that EGF and PMA/H2O2 employ partly the
common pathway leading to the phosphorylation of the same
tyrosine residue (Tyr-21) of β2-chimaerin. The results in Fig. 3
demonstrated that, in addition to Tyr-21, β2-chimaerin contains
other tyrosine phosphorylation sites. However, these sites
remain unidentified at present. Of interest, in the case of cell
stimulation with PMA plus H2O2, we found that, in addition to
Tyr-21, Tyr-153 was phosphorylated, implying that distinct
tyrosine residues are phosphorylated by different cell stimula-
tions. Although beyond the scope of this study, determination of
which SFK isozymes are mainly involved in the tyrosine
phosphorylation of β2-chimaerin, and identification of other
tyrosine phosphorylation sites are interesting subjects of future
investigation.
It is interesting to note that β1-chimaerin, the other splice
variant of β-chimaerin, lacks the N-terminally extended region
containing the tyrosine residue corresponding to Tyr-21 in β2-
chimaerin. Thus, the regulatory mechanisms of β1-chimaerin
activity should be quite different from those of β2-chimaerin
including the phosphorylation at Tyr-21. On the other hand, this
tyrosine residue is conserved in the closely related isoform, α2-
chimaerin (Tyr-11). However, we found that tyrosine phos-
phorylation of α2-chimaerin was barely detectable when
stimulated with EGF and PMA plus H2O2 (Fig. 1C and data
not shown), thus indicating that the control mechanisms of this
isoform is also distinct from those of β2-chimaerin. The
flanking sequence of Tyr-11 in α2-chimaerin (DTDEY*RPPV)
is slightly different from that of β2-chimaerin (DAEEY*QPPI).
Because SFKs prefer acidic amino acids in the flanking
sequences [33], a basic amino acid, Arg, at the +1 position may
cause the significantly less tyrosine-phosphorylation state of
α2-chimaerin. Moreover, α2-chimaerin was reported to form a
functional complex with cyclin-dependent kinase 5, collapsin
response mediator protein-2 and Sema 3A receptor in dorsal
root ganglion neurons [34,35]. It is thus possible that such a
unique conformation and subcellular localization of this
isoform probably caused by the α2-chimaerin-specific inter-
acting proteins may contribute to suppress the tyrosine phos-
phorylation state.
The Y21F mutant of β2-chimaerin is apparently more active
than the WT protein in EGF-stimulated cells (Fig. 4B). How is
β2-chimaerin negatively regulated through the Tyr-21 phos-
phorylation? The tyrosine phosphorylation of β2-chimaerin at
Tyr-21 may control the extent of association with its regulatory
protein, which should contain an SH2 domain and interact via
the phosphorylated Tyr-21, or, alternatively, may directly re-
duce its intrinsic GAP activity. Regarding the latter possibility,
interestingly, Tyr-21 is located in the vicinity of the steric
inhibitory region of Rac binding (Pro-23 and Pro-24) [21].
Thus, it is possible that the phosphorylation of Tyr-21 stabilizes
the autoinhibitory, intramolecular interaction. The modification
of β2-chimaerin GAP activity can only be demonstrated using
purified proteins in in vitro GAP assays. We thus attempted to
analyze direct effects of tyrosine phosphorylation of β2-
chimaerin on its GAP activity. However, because only a smallportion of the purified protein was tyrosine-phosphorylated by
active Src in vitro, we could not assess the negative effects of
Src-dependent tyrosine phosphorylation on GAP activity in
vitro. Further studies are required to address this issue.
β2-Chimaerin was recently reported to be activated by the
EGFR-PLCγ pathway [13]. However, SFK is not involved in the
EGFR-coupled activation of PLCγ [36]. Moreover, a PLC
inhibitor, U73122, did not inhibit the EGF-induced tyrosine-
phosphorylation of β2-chimaerin in the present work (data not
shown). We also recently found that diacylglycerol kinase γ
interacts with and activates β2-chimaerin in response to EGF
[37]. However, the interaction between diacylglycerol kinase γ
and β2-chimaerin was not inhibited by the SFK inhibitor
SU6656 (data not shown), which significantly inhibited the
phosphorylation at Tyr-21 ofβ2-chimaerin (Fig. 2A). Therefore,
an obvious possibility arises in which β2-chimaerin can be
regulated by at least two independent signaling pathways in
response to growth factors. One is the SFK-independent
pathway initiated by the activation of PLCγ and/or regulated
by diacylglycerol kinase γ. The other could be the SFK-
dependent pathway that phosphorylates Tyr-21 in the N-terminal
regulatory region. Of interest, these pathways conversely
regulate β2-chimaerin activity to each other. Thus, it is tempting
to speculate that the dynamic balance between the PLCγ and
SFK pathways, which functionally conflict with each other,
ultimately determines the level ofβ2-chimaerin activity. To fine-
tune protein functions, both activation and deactivation systems
are simultaneously required. Our finding on the negative
regulatory mechanism should help to explore in greater detail
how β2-chimaerin Rac1-GAP activity is controlled.
The proto-oncogene product, c-Src, as a representative SFK,
has been strongly implicated in the development, growth,
progression, and metastasis of a number of human cancers
including those of the colon, breast, pancreas, and brain [23,24].
Moreover, Rac1 was reported to be required for Src-induced
transformation [4]. In this case, Src tyrosine-phosphorylated
and activated Rac-GEFs, Vav2 and Tiam1. In the present study,
it is suggested that SFKs including c-Src negatively regulate a
Rac-GAP, β2-chimaerin, thereby elevating Rac1-GTP levels.
Thus, it is likely that c-Src enhances Rac1 activity cooperatively
through both activation of positive regulators of Rac1 (Rac-
GEFs) and inhibition of a negative regulator of Rac1 (β2-
chimaerin Rac-GAP). Recently, down-regulation of the β2-
chimaerin mRNA levels was found in some types of cancers
such as high-grade glioma [9] and mastocarcinoma [10,11],
suggesting that reduced expression of this gene contributes to
the development of the tumors. Interestingly, Src is highly
active in these tumors [23]. In addition to the reduced
expression, therefore, the Src-dependent reduction of GAP
activity may synergistically increase Rac-GTP levels, thereby
accelerating the tumor development.
Acknowledgements
This work was supported in part by grants from the Ministry
of Education, Culture, Sports, Science and Technology, the
Japanese Government.
1415M. Kai et al. / Biochimica et Biophysica Acta 1773 (2007) 1407–1415Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.bbamcr.2007.05.004.
References
[1] A. Hall, Rho GTPases and the actin cytoskeleton, Science 279 (1998)
509–514.
[2] L. Kjoller, A. Hall, Signaling to Rho GTPases, Exp. Cell Res. 253 (1999)
166–179.
[3] A. Schmidt, M.N. Hall, Signaling to the actin cytoskeleton, Annu. Rev.
Cell Dev. Biol. 14 (1998) 305–338.
[4] J.M. Servitja, M.J. Marinissen, A. Sodhi, X.R. Bustelo, J.S. Gutkind, Rac1
function is required for Src-induced transformation. Evidence of a role for
Tiam1 and Vav2 in Rac activation by Src, J. Biol. Chem. 278 (2003)
34339–34346.
[5] C. Hall, L. Lim, T. Leung, C1, see them all. Trends Biochem. Sci. 30
(2005) 169–171.
[6] C. Yang, M.G. Kazanietz, Divergence and complexities in DAG signaling:
looking beyond PKC, Trends Pharmacol. Sci. 24 (2003) 602–608.
[7] Y. Nishizuka, The molecular heterogeneity of protein kinase C and its
implications for cellular regulation, Nature 334 (1988) 661–665.
[8] C. Hall, G.J. Michael, N. Cann, G. Ferrari, M. Teo, T. Jacobs, C. Monfries,
L. Lim, α2-Chimaerin, a Cdc42/Rac1 regulator, is selectively expressed in
the rat embryonic nervous system and is involved in neuritogenesis in
N1E-115 neuroblastoma cells, J. Neurosci. 21 (2001) 5191–5202.
[9] S. Yuan, D.W. Miller, G.H. Barnett, J.F. Hahn, B.R. Williams,
Identification and characterization of human β2-chimaerin: association
with malignant transformation in astrocytoma, Cancer Res. 55 (1995)
3456–3461.
[10] P.L. Menna, G. Skilton, F.C. Leskow, D.F. Alonso, D.E. Gomez, M.G.
Kazanietz, Inhibition of aggressiveness of metastatic mouse mammary
carcinoma cells by the β2-chimaerin GAP domain, Cancer Res. 63 (2003)
2284–2291.
[11] C. Yang, Y. Liu, F.C. Leskow, V.M. Weaver, M.G. Kazanietz, Rac-GAP-
dependent inhibition of breast cancer cell proliferation by β2-chimerin,
J. Biol. Chem. 280 (2005) 24363–24370.
[12] M.J. Caloca, H. Wang, M.G. Kazanietz, Characterization of the Rac-GAP
(Rac-GTPase-activating protein) activity of β2-chimaerin, a ‘non-protein
kinase C’ phorbol ester receptor, Biochem. J. 375 (2003) 313–321.
[13] H. Wang, C. Yang, F.C. Leskow, J. Sun, B. Canagarajah, J.H. Hurley, M.G.
Kazanietz, Phospholipase Cγ/diacylglycerol-dependent activation of β2-
chimaerin restricts EGF-induced Rac signaling, EMBO J. 25 (2006)
2062–2074.
[14] T. Leung, B.E. How, E. Manser, L. Lim, Germ cell β-chimaerin, a new
GTPase-activating protein for p21rac, is specifically expressed during the
acrosomal assembly stage in rat testis, J. Biol. Chem. 268 (1993)
3813–3816.
[15] S. Imai, F. Sakane, H. Kanoh, Phorbol ester-regulated oligomerization of
diacylglycerol kinase δ linked to its phosphorylation and translocation,
J. Biol. Chem. 277 (2002) 35323–35332.
[16] S. Tsushima, M. Kai, K. Yamada, S. Imai, K. Houkin, H. Kanoh, F.
Sakane, Diacylglycerol kinase γ serves as an upstream suppressor of Rac1
and lamellipodium formation, J. Biol. Chem. 279 (2004) 28603–28613.
[17] T. Leung, B.E. How, E. Manser, L. Lim, Cerebellar β2-chimaerin, a
GTPase-activating protein for p21 ras-related rac is specifically expressed
in granule cells and has a unique N-terminal SH2 domain, J. Biol. Chem.
269 (1994) 12888–12892.
[18] Y.S. Bae, S.W. Kang, M.S. Seo, I.C. Baines, E. Tekle, P.B. Chock, S.G.
Rhee, Epidermal growth factor (EGF)-induced generation of hydrogenperoxide. Role in EGF receptor-mediated tyrosine phosphorylation,
J. Biol. Chem. 272 (1997) 217–221.
[19] P. Storz, A. Toker, Protein kinase D mediates a stress-induced NF-κB
activation and survival pathway, EMBO J. 22 (2003) 109–120.
[20] T.M. Wright, L.A. Rangan, H.S. Shin, D.M. Raben, Kinetic analysis of
1,2-diacylglycerol mass levels in cultured fibroblasts. Comparison of
stimulation by α-thrombin and epidermal growth factor, J. Biol. Chem.
263 (1988) 9374–9380.
[21] B. Canagarajah, F.C. Leskow, J.Y. Ho, H. Mischak, L.F. Saidi, M.G.
Kazanietz, J.H. Hurley, Structural mechanism for lipid activation of the
Rac-specific GAP, β2-chimaerin, Cell 119 (2004) 407–418.
[22] M.J. Caloca, H. Wang, A. Delemos, S. Wang, M.G. Kazanietz, Phorbol
esters and related analogs regulate the subcellular localization of β2-
chimaerin, a non-protein kinase C phorbol ester receptor, J. Biol. Chem.
276 (2001) 18303–18312.
[23] R.B. Irby, T.J. Yeatman, Role of Src expression and activation in human
cancer, Oncogene 19 (2000) 5636–5642.
[24] R. Ishizawar, S.J. Parsons, c-Src and cooperating partners in human cancer,
Cancer Cell 6 (2004) 209–214.
[25] A.F. Odell, J.L. Scott, D.F. Van Helden, Epidermal growth factor induces
tyrosine phosphorylation, membrane insertion, and activation of transient
receptor potential channel 4, J. Biol. Chem. 280 (2005) 37974–37987.
[26] R.A. Blake, M.A. Broome, X. Liu, J. Wu, M. Gishizky, L. Sun, S.A.
Courtneidge, SU6656, a selective src family kinase inhibitor, used to probe
growth factor signaling, Mol. Cell. Biol. 20 (2000) 9018–9027.
[27] T. Fukuyama, H. Ogita, T. Kawakatsu, T. Fukuhara, T. Yamada, T. Sato,
K. Shimizu, T. Nakamura, M. Matsuda, Y. Takai, Involvement of the c-Src-
Crk-C3G-Rap1 signaling in the nectin-induced activation of Cdc42 and
formation of adherens junctions, J. Biol. Chem. 280 (2005) 815–825.
[28] M. Maeda, Y. Shintani, M.J. Wheelock, K.R. Johnson, Src activation is not
necessary for transforming growth factor (TGF)-β-mediated epithelial to
mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly
inhibits TGF-β receptors I and II, J. Biol. Chem. 281 (2006) 59–68.
[29] R. Reinehr, S. Becker, A. Hongen, D. Haussinger, The Src family kinase
Yes triggers hyperosmotic activation of the epidermal growth factor
receptor and CD95, J. Biol. Chem. 279 (2004) 23977–23987.
[30] S.M. Thomas, J.S. Brugge, Cellular functions regulated by Src family
kinases, Annu. Rev. Cell Dev. Biol. 13 (1997) 513–609.
[31] E.A. Clark, W.G. King, J.S. Brugge, M. Symons, R.O. Hynes, Integrin-
mediated signals regulated by members of the rho family of GTPases,
J. Cell Biol. 142 (1998) 573–586.
[32] L.S. Price, J. Leng, M.A. Schwartz, G.M. Bokoch, Activation of Rac and
Cdc42 by integrins mediates cell spreading, Mol. Biol. Cell 9 (1998)
1863–1871.
[33] Z. Songyang, K.L. Carraway III, M.J. Eck, S.C. Harrison, R.A. Feldman,
M. Mohammadi, J. Schlessinger, S.R. Hubbard, D.P. Smith, C. Eng, M.J.
Lorenzo, B.J. Ponder, B.J. Mayer, L.C. Cantley, Catalytic specificity of
protein-tyrosine kinases is critical for selective signalling, Nature 373
(1995) 536–539.
[34] M. Brown, T. Jacobs, B. Eickholt, G. Ferrari, M. Teo, C. Monfries, R.Z.
Qi, T. Leung, L. Lim, C. Hall, α2-Chimaerin, cyclin-dependent Kinase
5/p35, and its target collapsin response mediator protein-2 are essential
components in semaphorin 3A-induced growth-cone collapse, J. Neurosci.
24 (2004) 8994–9004.
[35] R.Z. Qi, Y.P. Ching, H.F. Kung, J.H. Wang, α-Chimaerin exists in a
functional complex with the Cdk5 kinase in brain, FEBS Lett. 561 (2004)
177–180.
[36] D.Y. Noh, S.H. Shin, S.G. Rhee, Phosphoinositide-specific phospholipase
C and mitogenic signaling, Biochim. Biophys. Acta 1242 (1995) 99–113.
[37] S. Yasuda, M. Kai, S. Imai, H. Kanoh, F. Sakane, Diacylglycerol kinase γ
interacts with and activates β2-chimaerin, a Rac-specific GAP, in response
to epidermal growth factor, FEBS Lett. 581 (2007) 551–557.
